Patent focus on cancer chemotherapeutics V. Angiogenesis agents: September 2001 - August 2002

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 12, 2002, Pages 1763-1782

  Connell, Richard D ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

632; Angiogenesis; Antiangiogenesis; CEP 5214; CEP 7055; CP 547; DC101; Fibroblast growth factor (FGF); Fibroblast growth factor receptor (FGFR); Platelet derived growth factor receptor (PDGFR); PTK 787; Receptor tyrosine kinases inhibitor (TKI); SU 5416; SU 6668; Tie 2; Vascular endothelial growth factor (VEGF); Vascular endothelial growth factor receptor (VEGFR); ZD 6474

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FLT3 LIGAND; IMATINIB; IMIDAZOLE DERIVATIVE; NAPHTHYRIDINE DERIVATIVE; PENTRAXIN; PHTHALAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SEMAXANIB; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HUMAN; PATENT; PUBLISHING; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0036928020     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.12.1763     Document Type: Article

References (34)

1. RIBATTI D, VACCA A, NICO B, RONCALI L, DAMMACCO, F: Postnatal vasculogenesis. Mech. Dev. (2001) 100(2):157-163.
2. BROCK CS, LEE SM: Antiangiogenic strategies and vascular targeting in the treatment of lung cancer. Eur. Resp. J. (2002) 19(3):557-570.
3. HERBST RS, HIDALGO M, PIERSON AS, HOLDEN SN, BERGEN M, ECKHARDT SG: Angiogenesis inhibitors in clinical development for lung cancer. Semin. Oncol. (2002) 29(1 Suppl.4):66-77.
4. GOEL S, MANI S, PEREZ-SOLER R: Tyrosine kinase inhibitors: a clinical perspective. Current Oncology Reports (2002) 4(1):9-19.
5. CONNELL RD: Cancer chemotherapeutics - angiogenesis agents: October 1999 - March 2000. Expert Opin. Ther. Patents (2000) 10(6):767-786.
6. CONNELL RD, BEEBE JS: Patent focus on cancer chemotherapeutics. II angiogenesis agents: April 2000 - September (2000). Expert Opin. Ther. Patents (2001) 11(1):77-114.
7. CONNELL RD, BEEBE JS: Patent focus on cancer chemotherapeutics. III Angiogenesis agents: October 2000 - March 2001. Expert Opin. Ther. Patents (2001) 11(7):1171-1203.
8. CONNELL RD, BEEBE JS: Patent focus on cancer chemotherapeutics. IV Angiogenesis agents: April 2001 - August 2001. Expert Opin. Ther. Patents (2001) 11(12):1919-1945.
9. YANA I, SEIKI M: MT-MMPs play pivotal roles in cancer dissemination. Clin. Exp. Metastasis (2002) 19(3):209-215.
10. VIHINEN P, KAHARI VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer (2002) 99(2):157-166.
11. JACKSON C: Matrix metalloproteinases and angiogenesis. Curr. Opin. Nephrol. Hyperten. (2002) 11(3):295-299.
12. DOHERTY TM, ASOTRA K, PEI DQ et al.: Therapeutic developments in matrix metalloproteinase inhibition. Expert Opin. Ther. Patents (2002) 12(5):665-707.
13. WESTLIN WF: Integrins as targets of angiogenesis inhibition. Cancer J. (2001) 7(Suppl. 3):S139-43.
14. COOPER CR, CHAY CH, PIENTA KJ: The role of α(v)β(3) in prostate cancer progression. Neoplasia (2002) 4(3):191-194.
15. AL-OBEIDI FA, LAM KS: Development of inhibitors for protein tyrosine kinases. Oncogene (2000) 19:5690-5701.
16. LEVITZKI A: Protein tyrosine kinase inhibitors as therapeutic agents. Bioorg. Chem. Biol. Signal Transduction (2001) 211:1-15.
17. DUMAS J: Protein kinase inhibitors: emerging pharmacophores 1997 - 2000. Expert Opin. Ther. Patents (2001) 11(3):405-429.
18. ZWICK E, BANGE J, ULLRICH A: Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol. Med. (2002) 8(1):17-23.
19. HICKLIN DJ, WITTE L, ZHU ZP et al.: Monoclonal antibody strategies to block angiogenesis. Drug Discovery Today (2001) 6(10):517-528.
20. WOOLF AS, YUAN HT: Angiopoietin growth factors and Tie receptor tyrosine kinases in renal vascular development. Pediatric Nephrology (2001) 16(2):177-184.
21. JONES N, ILJIN K, DUMONT DJ, ALITALO K: Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nature Reviews Molecular Cell Biology (2001) 2(4):257-267.
22. Abbott confident Synthroid will stay on US market Scrip, July 2, 2001.
23. SHEWCHUK LM, HASSELL AM, ELLIS B et al.: Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop and C-terminal tail. Structure (2000) 8(11):1105-1113.
24. JEFFERS M, SHIMKETS R, PRAYAGA S et al.: Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer Res. (2001) 61(7):3131-3138.
25. PANDEY A, VOLKOTS DL, SEROOGY J et al.: Discovery of CT53518, a potent and oral inhibitor of FLT3 kinase targeted for the treatment of acute myelogenous leukaemia. 223rd ACS National Meeting, Orlando, USA (2002) MEDI 19.
26. HENNEQUIN LF, STOKES ESE, THOMAS AP et al.: Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure-activity relationship of a series of potent, orally-active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. (2002) 45(6):1300-1312.
27. WOOD JM, BOLD G, BUCHDUNGER E et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumour growth after oral administration. Cancer Res. (2000) 60(8):2178-89.
28. BOLD G, FREI J, FURET P et al.: CGP 79787D (PTK787/ZK222584), CGP 84738 NVP-AAC789, NVP-AAD777 and related 1-anilino-(4-pyridylmethyl)phthalazines as inhibitors of VEGF- and bFGF-induced angiogenesis. Drugs of the Future (2002) 27(1):43-55.
29. DREVS J, MULLER-DRIVER R, WITTIG C et al.: PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumour vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. (2002) 62(14):4015-4022.
30. ARRINGTON KL, COLL KE, FRALEY ME et al.: Development of 3-aryl- 5-(3-indolyl)pyridines as a novel class of KDR kinase inhibitors. 223rd ACS National Meeting, Orlando, USA (2002) MEDI 187.
31. HOFFMAN WF, ARRINGTON KL, COLL KE et al.: Design and synthesis of 2- acylamino-5-arylsubstituted oxazoles as kinase inhibitors of the VEGF receptor KDR. 223rd ACS National Meeting, Orlando, USA (2002) MEDI 181.
32. BILODEAU MT, COLL KE, CUNNINGHAM AM et al.: Development and in vivo evaluation of novel inhibitors of the VEGF receptor tyrosine kinase KDR (VEGFR-2). 223rd ACS National Meeting Orlando, USA (2002) MEDI 261.
33. FRALEY ME, ARRINGTON KL, COLL KE et al.: Design, synthesis and in vitrolin vivo characterization of three novel classes of VEGFR-2 (KDR) kinase inhibitors. 93rd Annual meeting of the American Association of Cancer Research (AACR) San Francisco, CA, USA (2002) Abstract 3676.
34. TOLCHER A, KARP DD, O'LEARY JJ et al.: A Phase I and biologic correlative study of an oral Vascular Endothelial Growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients (PTS) with advanced solid tumours. 38th annual meeting of the Amer. Soc. Clin. Oncol., Orlando FL, USA (2002) Abstract 334